Day: August 7, 2023

– Total Net Sales of $129.2 Million versus $147.9 million in Prior Year Second Quarter –– Net Income of $1.2 Million versus ($26.7) Million in Prior Year Second Quarter, which included non-cash after-tax charges of $28 million – – Adjusted EBITDA of $7.4 Million versus $4.8 Million in Prior Year Second Quarter –– Board of Directors Approves Another $0.14 Per Share Quarterly Dividend –– Provides Updated Full-Year Guidance – ST. PETERSBURG, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its second quarter 2023 results. Second Quarter Results For the second quarter ended June 30, 2023, net sales decreased 12.7% to $129.2 million, compared to second quarter 2022 net sales of $147.9 million. Pretax income was $1.4 million compared to a pretax loss of ($29.0) million...

Achieved over $200 million of revenue for first half of 2023Closed nine deals in the quarterPaid down $114 million of debt since separation SAN JOSE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) —  Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the second quarter ending June 30, 2023. “Our deal momentum continues, as we closed nine license agreements in the second quarter across a diverse group of pay-TV, OTT, consumer electronics and semiconductor customers in domestic and international markets, further validating the value of our growing intellectual property (IP) portfolio,” said Paul E. Davis, chief executive officer of Adeia. “After a strong first half of the year, we remain on track to achieve our goals for 2023 and we continue to make excellent progress towards our long-term strategic...

Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2023. “Akoya delivered strong financial performance in the second quarter, highlighted by record revenue and the milestone of the 1,000th publication featuring Akoya platforms, the industry’s largest and fastest growing publications volume,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. “With a leading position in spatial biology, consistent commercial and operational execution, and a recent financing to further increase the strength of our balance sheet, Akoya is well positioned to continue to drive...

– Delivered net income, positive Adjusted EBITDA and positive operating cash flow, while making significant capital expenditures to support business transformation – – Expects Positive Adjusted EBITDA in Q3 2023 – PEKIN, Ill., Aug. 07, 2023 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols and essential ingredients, reported its financial results for the quarter ended June 30, 2023. “We continue to pursue opportunities to maximize value through capital investments and onboarding strategic partners that share our vision. Our strategy is coming to fruition,” said Bryon McGregor, President and CEO of Alto Ingredients. “In the second quarter of 2023, improved ethanol crush margins complemented by favorable economics from our high-quality alcohol...

Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3;Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRINGTON, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the second quarter ended June 30, 2023 and provided key business updates. “During the second quarter, we completed a successful $12.4 million financing to strengthen the company’s balance sheet and support our istaroxime development efforts. We next plan to move the istaroxime program in cardiogenic shock...

SAN CLEMENTE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Results Second quarter 2023 revenue was $549.3 million, compared to $561.0 million in the same period last year. GAAP gross profit for the second quarter of 2023 was $192.3 million, as compared to $167.6 million in the same period last year. GAAP gross margin for the second quarter of 2023 was 35%, as compared to 30% in the same period last year. GAAP net loss for the second quarter of 2023 was $(9.9) million, or $(0.41) per diluted share, as compared to GAAP net loss of $(7.5) million, or $(0.31) per diluted share, for the second quarter of 2022. Adjusted diluted earnings...

Second Quarter 2023 Highlights:Revenue of $161.6 million, compared with $164.0 million in the same period last year GAAP net loss of $85.3 million, or $1.61 loss per diluted share, included a $97.1 million loss related to debt refinancing, compared with net income of $9.7 million, or $0.18 earnings per diluted share in the same period last year Non-GAAP net income of $20.6 million, or $0.36 per diluted share, compared with $20.0 million, or $0.35 per diluted share in the same period last yearPLAINVIEW, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its second quarter ended June 30, 2023. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation...

Delivers Record Revenue with Adjusted EBITDA Ahead of Guidance Raises 2023 GuidanceSecond quarter revenue of $124 million, up 8% year over year Second quarter GAAP net income (loss) of ($16) million Second quarter Adjusted EBITDA of ($4) million Updating 2023 guidance:Revenue of $474 million to $482 million, representing growth of 12% to 14% YoY GAAP net income (loss) of ($79) to ($83) million Adjusted EBITDA of ($23) million to ($27) millionBUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) —  ACV (Nasdaq: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, today reported results for its second quarter ended June 30, 2023. “We are very pleased with our strong second quarter results, with revenue once again above our guidance range and, along with year-over-year margin...

Second Quarter Revenue Increased 17% to $14.7 Million, Generated EPS of $0.10 BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended June 30, 2023. “We are pleased with our second quarter results, further highlighting our ability to drive both top-line growth and profitability,” stated Derek Dubner, red violet’s CEO. “We are seeing continued strength in new customer onboarding, pipeline expansion from higher-tier prospects, and robust customer conversion at all levels. Our consistent revenue growth and increasing profitability, which are driven by our distinct ability to meet strong industrywide demand for innovative, accurate, and highly-scalable identity solutions, bolster our position...